Hemostats Market by Type (Thrombin, Oxidised Regenerated Cellulose, Combination, Gelatin, Collagen), Application (Orthopedic Surgery, General Surgery, Gynecological), Formulation (Sponge, Powder, Matrix & Gel, Sheets & Pads) - Global Forecast to 2026
[230 Pages Report] The global Hemostats market size is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.1% during the forecast period. Growth in this market is driven by the growing volume of surgical procedures performed, rising focus on R&D, increasing incidence of sports-related injuries and spinal ailments, and rising focus on effective blood loss management in patients during surgeries. However, side effects and allergic reactions associated with hemostats are expected to hamper the adoption of these products.
To know about the assumptions considered for the study, Request for Free Sample Report
COVID -19 Impact on the Hemostats Market
With the WHO officially declaring the outbreak of COVID-19 a pandemic, a mix of established pharmaceutical and biopharmaceutical companies and small startups has stepped forward to develop treatments and vaccines that target the infection caused by the novel coronavirus. The COVID-19 outbreak has significantly impacted the availability of hospital resources worldwide. This has been primarily managed by dramatically reducing inpatient and outpatient services for other diseases and implementing infection prevention and control measures. the number of surgical procedures declined precipitously, with countries worldwide being affected by the pandemic
Global HemostatsMarket Dynamics
Driver: Growing Volume Of Surgical Procedures Performed
Adhesion formation is a major post-surgical complication, which results in healthcare complications and generally requires repeat surgeries for the treatment of affected patients. Post-surgical adhesion formation leads to different complications in different surgeries, such as severe abdominal pain in the case of abdominal surgeries, infertility in women after gynecological surgeries, and physical impairment of patients after neurological surgeries. Considering the severe effects of post-surgery adhesion formation in patients, the importance of products such as adhesion barriers is increasing in the market.
Over the years, there has been a significant rise in the number of surgical procedures performed across the globe. According to WHO estimations (2019), approximately 235 million major surgical procedures are undertaken worldwide every year. This is attributed to the growing prevalence of obesity and other lifestyle diseases, the rising geriatric population, the increasing prevalence of orthopedic conditions, and the increasing incidence of spinal and sports-related injuries.
According to the Heart and Circulatory Disease Statistics 2019 from the British Heart Foundation (UK), there has been a significant increase in the number of cardiac surgical procedures such as angioplasty and aortic valve replacement in the UK over the last decade, and this trend is expected to continue in the coming years.
Opportunity: Growth In The Number Of Hospitals & Surgical Centers
The number of hospitals and surgical centers is increasing in both developed and emerging countries. The demand for surgical equipment (including medical devices such as hemostats) is high in these newly established surgical centers and hospitals, owing to the increasing patient population base. For instance, in October 2020, the Prime Minister of the UK announced plans of investing USD 4.3 billion for 40 hospitals and certain schemes for future funding for 48 hospitals by 2030. In addition, in March 2021, Steward Health Care announced plans to construct a new hospital in Washington County.
Over the last decade, developing countries such as India and China have witnessed significant improvements in their respective healthcare infrastructure. According to an article published in January 2020, China announced to invest USD 4.6 billion for the construction of hospitals in Wuhan. According to the Commonwealth Fund in 2018, China has approximately 12,000 public hospitals and 21,000 private hospitals. Similarly, in June 2019, the Indian Ministry of Health and Family Welfare announced the opening of 22 new AIIMS across the country. The significant growth in the number of hospitals and surgical centers is expected to support the growth of the hemostats market, as these are key end users of the hemostats market.
Challenge: Dearth Of Skilled Personnel For The Effective Use Of Hemostats Products
Skilled professionals are required to handle hemostats as the improper closure of arteries after surgical procedures may lead to continuous bleeding or cause ischemia. Some devices even require several steps in sequence while using them. Based on the current scenario, the American College of Cardiology estimates a shortage of 21% of cardiac surgeons by 2025 in the US (Source: American Heart Association).
Currently, the lack of skilled surgeons, both in developed and developing economies, is one of the major factors limiting the adoption of these products. For instance, the Association of American Medical Colleges (AAMC) projects a shortage of about 122,000 physicians by 2032 in the US. Of these, a shortage of 12,000 medical specialists and 23,400 surgeons and 39,100 other specialists such as neurologists and radiologists is expected to occur by 2032.
The technology landscape and application areas of hemostats products are changing rapidly, owing to technological advancements in this field. This necessitates physicians and other healthcare providers to acquire the necessary skills to apply advanced hemostats products such as hemostats, bone graft substitutes, surgical sealants, and adhesives effectively. Therefore, surgeons and physicians in hospitals and clinics are reluctant to use advanced surgical products for wound closure.
The Thrombin-based hemostats segment is expected to grow at the highest CAGR during the forecast period
By type, the Hemostats market is segmented into thrombin-based hemostats, oxidized regenerated cellulose-based hemostats, combination hemostats, gelatin-based hemostats, and collagen-based hemostats. The thrombin-based hemostats segment accounted for the largest share in the hemostats market in 2020. The large share of this segment can primarily be attributed to the advantages associated with the use of thrombin-based hemostat.
The Matrix & gel hemostats segment of Diagnostic Devices accounted for the largest share of the Hemostats market in 2020
Based on formulation, the hemostats market is segmented into matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats. In 2020, the matrix & gel hemostats segment accounted for the largest share of the hemostats market. The large share of this segment can be attributed to the advantages associated with these hemostats, such as easy application, biocompatibility, and cost-effectiveness. On the other hand, the sponge hemostats segment is expected to witness the highest growth in the market during the forecast period due to the growing acceptance of these formulations by end users.
Orthopedic surgery accounted for the largest share of the Hemostats market in 2020
Based on application, the hemostats market is segmented into neurological surgery, cardiovascular surgery, general surgery, orthopedic surgery, gynecological surgery, reconstructive surgery, and other surgeries (urological, thoracic, and ENT surgeries). The orthopedic surgery segment accounted for the largest share of the hemostats market in 2020. The growing geriatric population, increasing incidence of sports injuries, and the growing prevalence of lifestyle disorders (such as arthritis, osteoporosis, and obesity) are some of the major factors responsible for the growing number of orthopedic surgeries performed globally. However, the reconstructive surgery segment is expected to grow at the highest CAGR during the forecast period. Growth in the number of facial cosmetic surgeries and breast reconstruction procedures are the major factors driving the growth of this segment
To know about the assumptions considered for the study, download the pdf brochure
North America accounted for the largest share of the Hemostats market in 2020
Based on the region, Hemostats market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In 2020, North America accounted for the largest share of the Hemostats market, followed by Europe. The large share of North America is majorly driven by the growing geriatric population and the increasing number of surgeries performed in the region and the strong presence of major market players in this region.
Some of the major players operating in this market are C.R. Bard (US), Baxter (US), Teleflex Incorporated (US), Ethicon (Subsidiary of Johnson & Johnson) ( US), Medtronic plc (Ireland), B. Braun Melsungen AG (Germany), Pfizer (US), etc. In 2020, Ethicon (Subsidiary of Johnson & Johnson) ( US) held the leading position in the market. The company has a strong geographic presence across the US, Asia, Europe, Middle East and Africa, & the Americas. Moreover, the company’s strong brand recognition and comprehensive product portfolio in the Hemostatsmarket is its key strength. Baxter (US) held the second position in the Hemostatsmarket in 2020.
Scope of the Report
|
Report Metric |
Details |
|
Market Size Available for Years |
2016–2026 |
|
Base Year Considered |
2020 |
|
Forecast Period |
2021–2026 |
|
Forecast Units |
Value (USD Billion) |
|
Segments Covered |
type, formulation, application, and Region |
|
Geographies Covered |
North America (US, Canada), Europe (Germany, France, UK, Spain, Italy, Russia, Switzerland, Belgium, and RoE), APAC (China, India, Japan, Australia, Singapore, New Zealand, South Korea, Indonesia, Malaysia, and the RoAPAC), Latin America (Brazil, Mexico, Rest of Latin America) and Middle East & Africa |
|
Companies Covered |
Baxter International Inc. (US), Ethicon ((US), C.R. Bard (US), B. Braun Melsungen AG (Germany), Medtronic plc (Ireland), Teleflex Incorporated (US), Integra Life Sciences (US), Hemostasis, LLC (US), Pfizer Inc. (US), Stryker (US), CyroLife Inc. (US), GELITA MEDICAL GmbH (Germany), Marine Polymer Technologies, Inc. (US), and Advanced Medical Solutions Group plc (UK), Meril Life Sciences Pvt. Ltd. (India), Katsan Medical Devices (Turkey), Tricol Biomedical, Inc. (US), STARSIL Hemostat (Germany), 3-D Matrix Medical Technology (Japan), Biom’Up (France), Medtrade Products Limited (UK), Altaylar Medical (Turkey), BioCer Entwicklungs-GmbH (Germany), Samyang Holdings Corporation (South Korea), Unilene (US), and Betatech Medical (Turkey). |
This research report categorizes the Hemostats market into the following segments and subsegments:
Type
- Thrombin-Based Hemostats
- Oxidized Regenerated Cellulose-Based Hemostats
- Combination Hemostats
- Gelatin-Based Hemostats
- Collagen-Based Hemostats
Formulation
- Matrix & Gel Hemostats
- Sheet & Pad Hemostats
- Sponge Hemostats
- Powder Hemostats
Application
- Orthopedic Surgery
- General Surgery
- Neurological Surgery
- Cardiovascular Surgery
- Reconstructive Surgery
- Gynecological Surgery
- Other Surgeries
Region
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Russia
- Switzerland
- Belgium
- RoE
- Asia Pacific
- China
- India
- Japan
- Australia
- Singapore
- New Zealand
- South Korea
- Indonesia
- Malaysia
- RoAPAC
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
Recent Developments:
- In 2020, Teleflex acquired Z-Medica, LLC (US), a privately held medical device company that manufactures and sells hemostatic (hemorrhage control) products marketed under the QuikClot Combat Gauze and QuikClot Control+ brand names to enhance its product portfolio.
- In 2020, Baxter announced 510(k) clearance from the US FDA for Peri-Strips Dry with Veritas Collagen Matrix product with Secure Grip. The product helps in mitigating bleeding during bariatric surgeries and other surgical procedures.
Frequently Asked Questions (FAQ):
What is the projected market value of the global Hemostats market?
The global market of Hemostasis is projected to reach USD 3.5 billion by 2026.
What is the estimated growth rate (CAGR) of the global Hemostats market for the next five years?
The global Hemostatsmarket is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.1% from 2021 to 2026.
Who are the major players offering Hemostatsin the market?
C.R. Bard (US), Baxter (US), Teleflex Incorporated (US), Ethicon (Subsidiary of Johnson & Johnson) ( US), Medtronic plc (Ireland), B. Braun Melsungen AG (Germany), Pfizer (US), etc
Which type segment of the global Hemostats market is expected to witness the highest growth?
The Combination Hemostats segment is projected to grow at the highest CAGR during the forecast period.
Which application segment is expected to grow at the highest CAGR during the forecast period?
Reconstructive Surgery to register the highest growth during the forecast period. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 27)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 33)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primary interviews: By company type, designation, and region
2.2 MARKET SIZE ESTIMATION
FIGURE 3 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 4 REVENUE SHARE ANALYSIS ILLUSTRATION—BAXTER INTERNATIONAL, INC.
FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 7 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
2.6 LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT: HEMOSTATS MARKET
2.8 COVID-19 HEALTH ASSESSMENT
2.9 COVID-19 ECONOMIC ASSESSMENT
2.10 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
3 EXECUTIVE SUMMARY (Page No. - 49)
FIGURE 11 HEMOSTATS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 12 HEMOSTATS MARKET, BY FORMULATION, 2021 VS. 2026 (USD MILLION)
FIGURE 13 HEMOSTATS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 14 HEMOSTATS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 52)
4.1 HEMOSTATS MARKET OVERVIEW
FIGURE 15 NEED TO MANAGE BLOOD LOSS IN PATIENTS DURING SURGICAL PROCEDURES TO DRIVE MARKET GROWTH
4.2 ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION & COUNTRY (2020)
FIGURE 16 MATRIX & GEL HEMOSTATS SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2020
4.3 HEMOSTATS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 INDIA TO REGISTER THE HIGHEST REVENUE GROWTH DURING THE FORECAST PERIOD
4.4 HEMOSTATS MARKET, BY TYPE (2021–2026)
FIGURE 18 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS WILL CONTINUE TO DOMINATE THE HEMOSTATS MARKET DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 56)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 HEMOSTATS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Growing volume of surgical procedures performed
TABLE 3 UK: NUMBER OF CARDIAC SURGICAL PROCEDURES, 2010-2019
5.2.1.2 Rising focus on R&D
5.2.1.3 Increasing incidence of sports-related injuries and spinal ailments
5.2.1.4 Rising focus on effective blood loss management in patients during surgeries
5.2.2 OPPORTUNITIES
5.2.2.1 Growth in the number of hospitals & surgical centers
5.2.2.2 Growing adoption of advanced hemostats in emerging markets
TABLE 4 COST OF SURGICAL PROCEDURES: US VS. INDIA (USD)
5.2.3 RESTRAINTS
5.2.3.1 Side effects and allergic reactions associated with hemostats
5.2.3.2 Highly consolidated market
5.2.4 CHALLENGES
5.2.4.1 Dearth of skilled personnel for the effective use of hemostats
5.2.4.2 Stringent regulatory framework
5.2.4.3 High cost of hemostats
5.3 COVID-19 IMPACT ANALYSIS
5.4 RANGES/SCENARIOS
FIGURE 20 PESSIMISTIC SCENARIO
FIGURE 21 OPTIMISTIC SCENARIO
FIGURE 22 REALISTIC SCENARIO
5.5 REGULATORY ANALYSIS
TABLE 5 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING HEMOSTATS
5.5.1 NORTH AMERICA
5.5.1.1 US
TABLE 6 CLASSIFICATION OF MEDICAL DEVICES BY THE US FDA
FIGURE 23 PREMARKET NOTIFICATION: 510(K) APPROVAL FOR MEDICAL DEVICES
5.5.1.2 Canada
FIGURE 24 APPROVAL PROCESS FOR CLASS III MEDICAL DEVICES IN CANADA
5.5.2 EUROPE
FIGURE 25 CE APPROVAL PROCESS IN EUROPE FOR HEMOSTATS
5.5.3 ASIA PACIFIC
5.5.3.1 Japan
TABLE 7 CLASSIFICATION OF MEDICAL DEVICES AND THE REVIEWING BODY IN JAPAN
5.5.3.2 China
TABLE 8 NMPA MEDICAL DEVICES CLASSIFICATION
5.5.3.3 India
TABLE 9 CLASSIFICATION OF HEMOSTATS IN INDIA
5.6 PORTER’S FIVE FORCES ANALYSIS
TABLE 10 PORTER’S FIVE FORCES ANALYSIS
5.6.1 THREAT OF NEW ENTRANTS
5.6.2 THREAT OF SUBSTITUTES
5.6.3 BARGAINING POWER OF SUPPLIERS
5.6.4 BARGAINING POWER OF BUYERS
5.6.5 INTENSITY OF COMPETITIVE RIVALRY
5.7 TECHNOLOGY ANALYSIS
5.8 VALUE CHAIN ANALYSIS
FIGURE 26 VALUE CHAIN ANALYSIS: MAXIMUM VALUE IS ADDED DURING THE MANUFACTURING PHASE
5.9 SUPPLY CHAIN ANALYSIS
FIGURE 27 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES
5.10 PATENT ANALYSIS
5.10.1 PATENT GRANTED TRENDS FOR HEMOSTATS
FIGURE 28 PATENT GRANTED TRENDS, JANUARY 2011–JULY 2021
5.10.2 JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 29 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR HEMOSTAT PATENTS, JANUARY 2011 TO JULY 2021
5.10.3 PUBLICATION TRENDS FOR HEMOSTATS
5.11 TRADE ANALYSIS
5.11.1 TRADE ANALYSIS FOR HEMOSTATS
TABLE 11 IMPORT DATA FOR HEMOSTATS, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 12 EXPORT DATA FOR HEMOSTATS, BY COUNTRY, 2016–2020 (USD MILLION)
5.12 PRICING ANALYSIS
TABLE 13 AVERAGE SELLING PRICE FOR HEMOSTATS
5.13 ECOSYSTEM ANALYSIS
FIGURE 30 HEMOSTATS MARKET: ECOSYSTEM ANALYSIS
5.13.1 ROLE IN THE ECOSYSTEM
FIGURE 31 KEY PLAYERS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR HEMOSTAT MANUFACTURERS
6 HEMOSTATS MARKET, BY TYPE (Page No. - 81)
6.1 INTRODUCTION
TABLE 14 HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 15 HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
6.2 THROMBIN-BASED HEMOSTATS
6.2.1 DEVELOPMENTS IN RECOMBINANT THROMBIN PRODUCTS TO SUPPORT THE GROWTH OF THIS MARKET
TABLE 16 MAJOR PRODUCTS IN THE THROMBIN-BASED HEMOSTATS MARKET
TABLE 17 THROMBIN-BASED HEMOSTATS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 18 THROMBIN-BASED HEMOSTATS MARKET, BY REGION, 2020–2026 (USD MILLION)
6.3 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS
6.3.1 VENDORS ARE EXPANDING THE AVAILABILITY OF THEIR ORC-BASED HEMOSTATIC AGENTS ACROSS UNTAPPED MARKETS IN THE APAC
TABLE 19 MAJOR PRODUCTS IN THE OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET
TABLE 20 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 21 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET, BY REGION, 2020–2026 (USD MILLION)
6.4 COMBINATION HEMOSTATS
6.4.1 ADVANCEMENTS IN COMBINATION MATERIALS ARE SUPPORTING THE GROWTH OF THIS SEGMENT
TABLE 22 MAJOR PRODUCTS IN THE COMBINATION HEMOSTATS MARKET
TABLE 23 COMBINATION HEMOSTATS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 24 COMBINATION HEMOSTATS MARKET, BY REGION, 2020–2026 (USD MILLION)
6.5 GELATIN-BASED HEMOSTATS
6.5.1 GELATIN-BASED HEMOSTATS OFFER HIGH ELASTICITY
TABLE 25 MAJOR PRODUCTS IN THE GELATIN-BASED HEMOSTATS MARKET
TABLE 26 GELATIN-BASED HEMOSTATS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 27 GELATIN-BASED HEMOSTATS MARKET, BY REGION, 2020–2026 (USD MILLION)
6.6 COLLAGEN-BASED HEMOSTATS
6.6.1 LOW COST AND REDUCED RISK OF DISEASE TRANSMISSION ARE PROMOTING THE ADOPTION OF COLLAGEN-BASED HEMOSTATS
TABLE 28 MAJOR PRODUCTS IN THE COLLAGEN-BASED HEMOSTATS MARKET
TABLE 29 COLLAGEN-BASED HEMOSTATS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 30 COLLAGEN-BASED HEMOSTATS MARKET, BY REGION, 2020–2026 (USD MILLION)
7 HEMOSTATS MARKET, BY FORMULATION (Page No. - 91)
7.1 INTRODUCTION
TABLE 31 HEMOSTATS MARKET, BY FORMULATION, 2016–2019 (USD MILLION)
TABLE 32 HEMOSTATS MARKET, BY FORMULATION, 2020–2026 (USD MILLION)
7.2 MATRIX & GEL HEMOSTATS
7.2.1 MATRIX & GEL HEMOSTATS ENHANCE PLATELET AGGREGATION
TABLE 33 MATRIX & GEL HEMOSTATS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 34 MATRIX & GEL HEMOSTATS MARKET, BY REGION, 2020–2026 (USD MILLION)
7.3 SHEET & PAD HEMOSTATS
7.3.1 SHEET & PAD HEMOSTATS CAN BE CUT INTO ANY SHAPE OR SIZE, DEPENDING ON THE SURGICAL WOUND
TABLE 35 SHEET & PAD HEMOSTATS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 36 SHEET & PAD HEMOSTATS MARKET, BY REGION, 2020–2026 (USD MILLION)
7.4 SPONGE HEMOSTATS
7.4.1 SPONGE HEMOSTATS TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
TABLE 37 SPONGE HEMOSTATS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 38 SPONGE HEMOSTATS MARKET, BY REGION, 2020–2026 (USD MILLION)
7.5 POWDER HEMOSTATS
7.5.1 POWDER FORMULATIONS CAN BE SPRAYED DIRECTLY ON THE WOUND
TABLE 39 POWDER HEMOSTATS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 40 POWDER HEMOSTATS MARKET, BY REGION, 2020–2026 (USD MILLION)
8 HEMOSTATS MARKET, BY APPLICATION (Page No. - 97)
8.1 INTRODUCTION
TABLE 41 HEMOSTATS MARKET, BY APPLICATION, 2016–2019 (USD MILLION)
TABLE 42 HEMOSTATS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
8.2 ORTHOPEDIC SURGERY
8.2.1 ORTHOPEDIC SURGERY IS THE LARGEST APPLICATION SEGMENT FOR HEMOSTATS
TABLE 43 HEMOSTATS MARKET FOR ORTHOPEDIC SURGERY, BY REGION, 2016–2019 (USD MILLION)
TABLE 44 HEMOSTATS MARKET FOR ORTHOPEDIC SURGERY, BY REGION, 2020–2026 (USD MILLION)
8.3 GENERAL SURGERY
8.3.1 INCREASING NUMBER OF HERNIA REPAIR PROCEDURES TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 45 HEMOSTATS MARKET FOR GENERAL SURGERY, BY REGION, 2016–2019 (USD MILLION)
TABLE 46 HEMOSTATS MARKET FOR GENERAL SURGERY, BY REGION, 2020–2026 (USD MILLION)
8.4 NEUROLOGICAL SURGERY
8.4.1 GROWING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH
TABLE 47 HEMOSTATS MARKET FOR NEUROLOGICAL SURGERY, BY REGION, 2016–2019 (USD MILLION)
TABLE 48 HEMOSTATS MARKET FOR NEUROLOGICAL SURGERY, BY REGION, 2020–2026 (USD MILLION)
8.5 CARDIOVASCULAR SURGERY
8.5.1 RISING PREVALENCE OF CVD TO DRIVE THE ADOPTION OF HEMOSTATS
TABLE 49 HEMOSTATS MARKET FOR CARDIOVASCULAR SURGERY, BY REGION, 2016–2019 (USD MILLION)
TABLE 50 HEMOSTATS MARKET FOR CARDIOVASCULAR SURGERY, BY REGION, 2020–2026 (USD MILLION)
8.6 RECONSTRUCTIVE SURGERY
8.6.1 GROWING NUMBER OF FACIAL COSMETIC SURGERIES TO SUPPORT MARKET GROWTH
TABLE 51 HEMOSTATS MARKET FOR RECONSTRUCTIVE SURGERY, BY REGION, 2016–2019 (USD MILLION)
TABLE 52 HEMOSTATS MARKET FOR RECONSTRUCTIVE SURGERY, BY REGION, 2020–2026 (USD MILLION)
8.7 GYNECOLOGICAL SURGERY
8.7.1 HEMOSTATS ARE COMMONLY USED IN C-SECTION PROCEDURES TO CONTROL SURGICAL BLEEDING AND RELATED COMPLICATIONS
TABLE 53 C-SECTION SURGERIES PER 1,000 BIRTHS (2018)
TABLE 54 HEMOSTATS MARKET FOR GYNECOLOGICAL SURGERY, BY REGION, 2016–2019 (USD MILLION)
TABLE 55 HEMOSTATS MARKET FOR GYNECOLOGICAL SURGERY, BY REGION, 2020–2026 (USD MILLION)
8.8 OTHER SURGERIES
TABLE 56 HEMOSTATS MARKET FOR OTHER SURGERIES, BY REGION, 2016–2019 (USD MILLION)
TABLE 57 HEMOSTATS MARKET FOR OTHER SURGERIES, BY REGION, 2020–2026 (USD MILLION)
9 HEMOSTATS MARKET, BY REGION (Page No. - 109)
9.1 INTRODUCTION
TABLE 58 HEMOSTATS MARKET, BY REGION, 2016–2019 (USD MILLION)
TABLE 59 HEMOSTATS MARKET, BY REGION, 2020–2026 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 32 NORTH AMERICA: HEMOSTATS MARKET SNAPSHOT
TABLE 60 NORTH AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
TABLE 61 NORTH AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
TABLE 62 NORTH AMERICA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 63 NORTH AMERICA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 64 NORTH AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2016–2019 (USD MILLION)
TABLE 65 NORTH AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2020–2026 (USD MILLION)
TABLE 66 NORTH AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2016–2019 (USD MILLION)
TABLE 67 NORTH AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
9.2.1 US
9.2.1.1 The US dominates the North American hemostats market
TABLE 68 US: KEY MACROINDICATORS
TABLE 69 US: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 70 US: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Growing geriatric population and the increasing volume of surgeries to drive the demand for hemostats in Canada
TABLE 71 SURGICAL PROCEDURES PERFORMED IN CANADA, 2019
TABLE 72 CANADA: KEY MACROINDICATORS
TABLE 73 CANADA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 74 CANADA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.3 EUROPE
TABLE 75 EUROPE: HEMOSTATS MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
TABLE 76 EUROPE: HEMOSTATS MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
TABLE 77 EUROPE: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 78 EUROPE: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 79 EUROPE: HEMOSTATS MARKET, BY FORMULATION, 2016–2019 (USD MILLION)
TABLE 80 EUROPE: HEMOSTATS MARKET, BY FORMULATION, 2020–2026 (USD MILLION)
TABLE 81 EUROPE: HEMOSTATS MARKET, BY APPLICATION, 2016–2019 (USD MILLION)
TABLE 82 EUROPE: HEMOSTATS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 High healthcare expenditure in Germany to favor market growth
TABLE 83 SURGICAL PROCEDURES PERFORMED IN GERMANY, 2019
TABLE 84 GERMANY: KEY MACROINDICATORS
TABLE 85 GERMANY: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 86 GERMANY: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.3.2 UK
9.3.2.1 Growing volume of hernia repair and cardiovascular surgeries in the UK to drive market growth
TABLE 87 SURGICAL PROCEDURES PERFORMED IN THE UK, 2019
TABLE 88 UK: KEY MACROINDICATORS
TABLE 89 UK: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 90 UK: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 Presence of a well-established healthcare system and growing geriatric population to propel market growth
TABLE 91 SURGICAL PROCEDURES PERFORMED IN FRANCE, 2019
TABLE 92 FRANCE: KEY MACROINDICATORS
TABLE 93 FRANCE: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 94 FRANCE: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.3.4 ITALY
9.3.4.1 Increasing volume of surgeries to drive the demand for hemostats in the country
TABLE 95 SURGICAL PROCEDURES PERFORMED IN ITALY, 2019
TABLE 96 ITALY: KEY MACROINDICATORS
TABLE 97 ITALY: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 98 ITALY: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 Growing healthcare budget and rising efforts for boosting the local manufacturing of medical products to drive market growth
TABLE 99 SURGICAL PROCEDURES PERFORMED IN SPAIN, 2019
TABLE 100 SPAIN: KEY MACROINDICATORS
TABLE 101 SPAIN: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 102 SPAIN: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.3.6 RUSSIA
9.3.6.1 Rising public healthcare expenditure to support market growth
TABLE 103 RUSSIA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 104 RUSSIA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.3.7 SWITZERLAND
9.3.7.1 Increasing public health insurance coverage to drive the number of surgical procedures
TABLE 105 SURGICAL PROCEDURES PERFORMED IN SWITZERLAND, 2019
TABLE 106 SWITZERLAND: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 107 SWITZERLAND: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.3.8 BELGIUM
9.3.8.1 Increasing demand for value-based healthcare services to drive market growth
TABLE 108 SURGICAL PROCEDURES PERFORMED IN BELGIUM, 2019
TABLE 109 BELGIUM: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 110 BELGIUM: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.3.9 REST OF EUROPE
TABLE 111 ROE: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 112 ROE: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 33 APAC: HEMOSTATS MARKET SNAPSHOT
TABLE 113 ASIA PACIFIC: HEMOSTATS MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
TABLE 114 ASIA PACIFIC: HEMOSTATS MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
TABLE 115 ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 116 ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 117 ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION, 2016–2019 (USD MILLION)
TABLE 118 ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION, 2020–2026 (USD MILLION)
TABLE 119 ASIA PACIFIC: HEMOSTATS MARKET, BY APPLICATION, 2016–2019 (USD MILLION)
TABLE 120 ASIA PACIFIC: HEMOSTATS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
9.4.1 CHINA
9.4.1.1 Growing number of hospitals and healthcare policy reforms are driving the growth of the hemostats market
TABLE 121 CHINA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 122 CHINA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Strong healthcare system and rising geriatric population to support market growth in Japan
TABLE 123 JAPAN: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 124 JAPAN: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Rising healthcare awareness and favorable government support to propel market growth in India
TABLE 125 INDIA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 126 INDIA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.4.4 AUSTRALIA
9.4.4.1 Rising prevalence of chronic diseases to drive market growth
TABLE 127 AUSTRALIA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 128 AUSTRALIA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.4.5 SOUTH KOREA
9.4.5.1 Growing number of cosmetic surgeries to drive the demand for hemostats in South Korea
TABLE 129 SURGICAL PROCEDURES IN SOUTH KOREA, 2019
TABLE 130 SOUTH KOREA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 131 SOUTH KOREA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.4.6 SINGAPORE
9.4.6.1 Government initiatives to promote the country’s healthcare services to support market growth
TABLE 132 SINGAPORE: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 133 SINGAPORE: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.4.7 NEW ZEALAND
9.4.7.1 Increasing number of bariatric surgeries to propel market growth
TABLE 134 NEW ZEALAND: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 135 NEW ZEALAND: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.4.8 INDONESIA
9.4.8.1 Indonesia offers lucrative growth opportunities for players in the hemostats market
TABLE 136 INDONESIA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 137 INDONESIA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.4.9 MALAYSIA
9.4.9.1 Low healthcare costs, modern medical technology, and highly qualified doctors to favor market growth in the country
TABLE 138 MALAYSIA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 139 MALAYSIA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.4.10 REST OF ASIA PACIFIC
TABLE 140 ROAPAC: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 141 ROAPAC: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.5 LATIN AMERICA
TABLE 142 LATIN AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
TABLE 143 LATIN AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
TABLE 144 LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 145 LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 146 LATIN AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2016–2019 (USD MILLION)
TABLE 147 LATIN AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2020–2026 (USD MILLION)
TABLE 148 LATIN AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2016–2019 (USD MILLION)
TABLE 149 LATIN AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
9.5.1 BRAZIL
9.5.1.1 Brazil accounted for the largest share of the LATAM market in 2020
TABLE 150 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 151 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.5.2 MEXICO
9.5.2.1 Low-cost surgeries are driving medical tourism in Mexico
TABLE 152 MEXICO: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 153 MEXICO: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.5.3 REST OF LATIN AMERICA
TABLE 154 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 155 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
9.6.1 MEA IS THE SMALLEST REGIONAL MARKET FOR HEMOSTATS
TABLE 156 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
TABLE 157 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2020–2026 (USD MILLION)
TABLE 158 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY FORMULATION, 2016–2019 (USD MILLION)
TABLE 159 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY FORMULATION, 2020–2026 (USD MILLION)
TABLE 160 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY APPLICATION, 2016–2019 (USD MILLION)
TABLE 161 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 166)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
TABLE 162 OVERVIEW OF STRATEGIES ADOPTED BY KEY HEMOSTAT PLAYERS
10.3 REVENUE ANALYSIS
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN THE HEMOSTATS MARKET
10.4 MARKET SHARE ANALYSIS
FIGURE 35 HEMOSTATS MARKET SHARE ANALYSIS, 2020
TABLE 163 HEMOSTATS MARKET: DEGREE OF COMPETITION
10.5 COMPETITIVE LEADERSHIP MAPPING
FIGURE 36 HEMOSTATS MARKET: COMPETITIVE LEADERSHIP MAPPING (2020)
10.6 COMPETITIVE LEADERSHIP MAPPING FOR SMES/START-UPS
FIGURE 37 HEMOSTATS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR SMES & START-UPS (2020)
10.7 COMPANY FOOTPRINT
TABLE 164 COMPANY FOOTPRINT
TABLE 165 COMPANY TYPE FOOTPRINT
TABLE 166 COMPANY REGIONAL FOOTPRINT
10.8 COMPETITIVE SCENARIO
10.8.1 DEALS
TABLE 167 KEY DEALS, JANUARY 2018– JUNE 2021
10.8.2 PRODUCT LAUNCHES & APPROVALS
TABLE 168 KEY PRODUCT LAUNCHES & APPROVALS, JANUARY 2018– JUNE 2021
10.8.3 OTHER DEVELOPMENTS
TABLE 169 OTHER DEVELOPMENTS, JANUARY 2018– JUNE 2021
11 COMPANY PROFILES (Page No. - 181)
11.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
11.1.1 BECTON, DICKINSON & COMPANY (C. R. BARD)
TABLE 170 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
11.1.2 BAXTER INTERNATIONAL, INC.
TABLE 171 BAXTER INTERNATIONAL: BUSINESS OVERVIEW
FIGURE 39 BAXTER INTERNATIONAL: COMPANY SNAPSHOT (2020)
11.1.3 TELEFLEX INCORPORATED
TABLE 172 TELEFLEX INCORPORATED: BUSINESS OVERVIEW
FIGURE 40 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2020)
11.1.4 B. BRAUN MELSUNGEN AG
TABLE 173 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
FIGURE 41 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2020)
11.1.5 JOHNSON & JOHNSON (ETHICON, INC.)
TABLE 174 JOHNSON & JOHNSON: BUSINESS OVERVIEW
FIGURE 42 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2020)
11.1.6 MEDTRONIC PLC
TABLE 175 MEDTRONIC PLC: BUSINESS OVERVIEW
FIGURE 43 MEDTRONIC PLC: COMPANY SNAPSHOT (2020)
11.1.7 HEMOSTASIS, LLC
TABLE 176 HEMOSTASIS, LLC: BUSINESS OVERVIEW
11.1.8 PFIZER INC.
TABLE 177 PFIZER INC.: BUSINESS OVERVIEW
FIGURE 44 PFIZER INC.: COMPANY SNAPSHOT (2020)
11.1.9 STRYKER
TABLE 178 STRYKER CORPORATION: BUSINESS OVERVIEW
FIGURE 45 STRYKER: COMPANY SNAPSHOT (2020)
11.1.10 CRYOLIFE, INC.
TABLE 179 CRYOLIFE, INC.: BUSINESS OVERVIEW
FIGURE 46 CRYOLIFE, INC.: COMPANY SNAPSHOT (2020)
11.1.11 MARINE POLYMER TECHNOLOGIES
TABLE 180 MARINE POLYMER TECHNOLOGIES: BUSINESS OVERVIEW
11.1.12 GELITA MEDICAL GMBH
TABLE 181 GELITA MEDICAL GMBH: BUSINESS OVERVIEW
11.1.13 INTEGRA LIFESCIENCES HOLDINGS CORPORATION
TABLE 182 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 47 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020)
11.1.14 ADVANCED MEDICAL SOLUTIONS GROUP PLC
TABLE 183 ADVANCED MEDICAL SOLUTIONS GROUP PLC: BUSINESS OVERVIEW
FIGURE 48 ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY SNAPSHOT (2020)
11.1.15 BETATECH MEDICAL
TABLE 184 BETATECH MEDICAL: BUSINESS OVERVIEW
11.1.16 MERIL LIFE SCIENCES PVT. LTD.
TABLE 185 MERIL LIFE SCIENCES PVT. LTD.: BUSINESS OVERVIEW
11.1.17 SAMYANG HOLDINGS CORPORATION
TABLE 186 SAMYANG HOLDINGS CORPORATION: BUSINESS OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
11.2 OTHER PLAYERS
11.2.1 BIOM’UP
11.2.2 BIOCER ENTWICKLUNGS-GMBH
11.2.3 UNILENE
11.2.4 KATSAN MEDICAL DEVICES
11.2.5 TRICOL BIOMEDICAL INC.
11.2.6 STARSIL HEMOSTAT
11.2.7 3-D MATRIX MEDICAL TECHNOLOGY
11.2.8 MEDTRADE PRODUCTS LIMITED
11.2.9 ALTAYLAR MEDICAL
12 APPENDIX (Page No. - 223)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
The study involved four major activities in estimating the current size of the Hemostats market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
Extensive primary research was conducted after acquiring knowledge about the global market scenario through secondary research. Primary interviews were conducted from both the demand (Medical Practitioners, Hospital Directors) and supply sides (Marketing Managers, Regional/Area Sales Managers, Product Managers/Technology Experts, Import/Export Heads, Distribution Channel Partners).
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the Hemostats market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research
- The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the Hemostatsindustry.
Report Objectives
- To define, describe, and forecast the global Hemostats market based on type, formulation, application, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific, Latin America and Middle East & Africa
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, new product launches, expansions, regulatory approvals, and agreements in the Hemostats market
Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
- Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company
- Geographic Analysis: Further breakdown of the hemostats market into specific countries/regions in the Rest of Europe, Rest of Asia Pacific, Rest of Latin America and the Rest of the World
Get in-depth analysis of the COVID-19 impact on the Hemostats Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Hemostats Market
Request For Special Pricing
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Hemostats Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Hemostats Market